ARTICLE | Company News

Sutro, Celgene revamping immuno-oncology deal

August 10, 2017 5:00 PM UTC

Sutro Biopharma Inc. (South San Francisco, Calif.) said it is refocusing a 2014 immuno-oncology multi-specific antibody and antibody-drug conjugate (ADC) deal with Celgene Corp. (NASDAQ:CELG). As part of the new agreement, the partners terminated Celgene's option to acquire Sutro.

In the original 2014 deal, the companies partnered to jointly develop six bispecific antibodies or ADCs to treat cancer using Sutro's cell-free protein synthesis technology. Celgene would get worldwide rights to the first program to reach IND status, plus ex-U.S. rights to any additional program. ...